In neuro news:

The American Academy of Neurology (AAN) is calling for more research on the use of medical marijuana for brain, spine and nervous system disorders. The AAN supports the reclassification of marijuana-based products by the federal government from their current status as a Schedule I drug to improve access for study of marijuana or cannabinoids under approved research protocols. In a position paper, AAN member Anup Patel, MD, stated that the AAN does not advocate for the legalization of marijuana-based products for use in brain and nervous system disorders at this time, and that further studies on the potentially toxic effects of marijuana must be performed.

Get the full story at Workers’ Compensation Institute 360 here.

Leave a Comment

Your email address will not be published. Required fields are marked *